We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
+30.04%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$647M
AUM Growth
-$1.41M
Cap. Flow
-$92.7M
Cap. Flow %
-14.32%
Top 10 Hldgs %
48.48%
Holding
76
New
6
Increased
14
Reduced
49
Closed
5

Top Buys

Rank Stock Value
1
ALKS icon
Alkermes
ALKS
+$17.1M
2
BMY icon
Bristol-Myers Squibb
BMY
+$13.1M
3
EGRX
Eagle Pharmaceuticals, Inc.
EGRX
+$8.98M
4
EPRS
EPIRUS BIOPHARMACEUTICALS INC COM
EPRS
+$6.6M
5
HRTX icon
Heron Therapeutics
HRTX
+$6.43M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$33.6M
2
RCPT
RECEPTOS INC COM STK (DE)
RCPT
+$31.8M
3
TPST icon
Tempest Therapeutics
TPST
+$12.9M
4
PBYI icon
Puma Biotechnology
PBYI
+$11.3M
5
KITE
Kite Pharma, Inc.
KITE
+$10.4M

Sector Composition

Rank Sector Weight
1 Healthcare 72.76%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARAV
51
DELISTED
Aravive, Inc. Common Stock
ARAV
$3.12M 0.48%
28,333
-5,000
-15% -$587K
NSTG
52
DELISTED
NanoString Technologies, Inc.
NSTG
$2.8M 0.43%
275,000
-25,000
-8% -$307K
DERM
53
DELISTED
Dermira, Inc.
DERM
$2.61M 0.4%
170,000
-30,000
-15% -$504K
IMDZ
54
DELISTED
Immune Design Corp.
IMDZ
$2.51M 0.39%
119,000
-21,000
-15% -$548K
KIN
55
DELISTED
Kindred Biosciences, Inc.
KIN
$2.35M 0.36%
328,497
-21,503
-6% -$148K
NGNE icon
56
Neurogene
NGNE
$718M
$2.3M 0.36%
13,995
-1,005
-7% -$204K
AGRX
57
DELISTED
Agile Therapeutics
AGRX
$1.69M 0.26%
91
+16
+21% +$280K
CLRB icon
58
Cellectar Biosciences
CLRB
$20.1M
$1.65M 0.25%
18
– –
BLCM
59
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$1.18M 0.18%
5,100
-900
-15% -$218K
AKBA icon
60
Akebia Therapeutics
AKBA
$346M
$1.11M 0.17%
100,300
-17,700
-15% -$188K
ASND icon
61
Ascendis Pharma A/S
ASND
$16B
$1.07M 0.16%
+61,500
New +$1.12M
VCYT icon
62
Veracyte
VCYT
$3.71B
$984K 0.15%
135,190
+34,990
+35% +$287K
GALT icon
63
Galectin Therapeutics
GALT
$203M
$959K 0.15%
286,200
-25,800
-8% -$92.2K
CLLS
64
Cellectis
CLLS
$281M
$865K 0.13%
+25,000
New +$907K
SCYX icon
65
SCYNEXIS
SCYX
$51.2M
$825K 0.13%
1,242
-8
-0.6% -$6.57K
AGTC
66
DELISTED
Applied Genetic Technologies Corporation
AGTC
$520K 0.08%
26,010
-34,590
-57% -$773K
PTCT icon
67
PTC Therapeutics
PTCT
$5.78B
$517K 0.08%
8,500
-1,500
-15% -$91.5K
NVRO
68
DELISTED
NEVRO CORP.
NVRO
$407K 0.06%
8,500
-1,500
-15% -$65.1K
AKTX
69
Akari Therapeutics
AKTX
$13.1M
$218K 0.03%
36
-2
-5% -$50K
SAGE
70
DELISTED
Sage Therapeutics
SAGE
$43K 0.01%
850
-150
-15% -$6.45K
ADVM
71
DELISTED
Adverum Biotechnologies
ADVM
– –
-6,500
Closed -$3.51M
BMY icon
72
CALL
Bristol-Myers Squibb
BMY
$130B
– –
-5,000
Closed -$3.7M
ASPX
73
DELISTED
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
– –
-100,000
Closed -$5.25M
CELG
74
DELISTED
Celgene Corp
CELG
– –
-300,000
Closed -$33.6M
1 2
3

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return

Cormorant Asset Management's Q1 2015 Portfolio in Review

As of Q1 2015, Cormorant Asset Management held 76 positions worth $647M, down 0.22% from $649M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Cormorant Asset Management withdrew a net $92.7M in Q1 2015, closing 5 positions and reducing 49 holdings. Its most notable exit was Celgene Corp, an estimated $33.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 73% of assets, up from 69% a quarter earlier.

Against the trend, Cormorant Asset Management opened a new position in Epizyme, Inc worth $5M.

  • Cormorant Asset Management's largest Q1 2015 buy was Epizyme, Inc: 266,250 shares worth $5M.
  • Cormorant Asset Management added most to Alkermes in Q1 2015, an estimated $17.1M increase.
  • Cormorant Asset Management's biggest Q1 2015 reduction was RECEPTOS INC COM STK (DE), cutting an estimated $31.8M.
  • Cormorant Asset Management fully exited Celgene Corp in Q1 2015, selling an estimated $33.6M.
  • Cormorant Asset Management's ten largest holdings make up 48% of its $647M portfolio in Q1 2015.
  • Cormorant Asset Management opened 6 new positions and closed 5 in Q1 2015.
  • Cormorant Asset Management's portfolio value fell 0.22% quarter-over-quarter to $647M.

Based on Cormorant Asset Management's 13F filing for Q1 2015, filed 15 May 2015.